Home > Healthcare > Pharmaceuticals > Drug Delivery > Transdermal Drug Delivery Systems Market
Transdermal Drug Delivery Systems Market Share
- Report ID: GMI5548
- Published Date: Apr 2023
- Report Format: PDF
Transdermal Drug Delivery System Market Share
Key players in the transdermal drug delivery system market are:
- Novartis
- Mylan
- Amneal Pharmaceuticals Inc
- Zydus Pharmaceuticals, Inc
- UCB
- Hisamitsu Pharmaceutical Co Inc
- Corium Inc
- Micropoint Technologies
- Sparsha Pharma International Pvt. Ltd.,
- Luye Pharma.
Companies operating in this business vertical are indulging strategic associations and drug R&D projects to strengthen their market standing.
Frequently Asked Questions (FAQ) :
Global market for transdermal drug delivery system was worth more than USD 29 billion in 2022 and is poised to exhibit over 8% CAGR during 2023-2032, owing to the mounting burden of chronic health disorders.
Transdermal patches segment is speculated to be worth over USD 35.5 billion by 2032, given the consistent technological developments in existing drug delivery systems.
Pain management segment is estimated to reach over USD 19.5 billion by 2032, driven by the rapid surge in the incidences of cancer worldwide.
Major companies in the transdermal drug delivery system market are Novartis, Mylan, Amneal Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., UCB, Hisamitsu Pharmaceutical Co., Inc., Corium, Inc., Micropoint Technologies, Sparsha Pharma International Pvt. Ltd., and Luye Pharma.
Transdermal Drug Delivery System Market Scope
×
Get a free sample of
Transdermal Drug Delivery System Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below